BAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Baxter International is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is showing a short-term bullish setup, but the bigger picture is mixed: analyst sentiment has turned more cautious, there is no recent news catalyst, and the pattern-based trend outlook points to weakness over the next 1 day, 1 week, and 1 month. Since you are unwilling to wait for a better entry, I would not buy here.
The chart trend is constructive in the very near term: MACD histogram is positive and expanding, and moving averages are bullish with SMA_5 > SMA_20 > SMA_200. Price at 22.70 is above the pivot (21.124) and near first resistance (R1 22.398), suggesting momentum has improved. However, RSI_6 at 74.85 is stretched, which usually means the move is already extended. The stock trend model is also bearish from here, implying downside probability in the near term despite the current bounce.
["Bullish moving average alignment (SMA_5 > SMA_20 > SMA_200)", "Positive and expanding MACD histogram", "Options flow is bullish with low put-call ratios", "Congress trading data is net positive with more purchases than sales", "Barclays recently raised its price target to 27 and kept Overweight"]
["Citi downgraded Baxter to Sell and cut its target to 17", "Goldman Sachs cut its target to 17 and kept Neutral", "No news in the past week, so no fresh catalyst", "Pattern-based trend outlook suggests negative returns over the next day, week, and month", "RSI is elevated, so the stock looks extended after the move"]
No usable latest-quarter financial snapshot was provided due to data error, so I cannot assess the most recent quarter’s revenue or EPS trend directly. The analyst notes do suggest the latest quarter had ongoing operational and margin headwinds, with declining sales and sharply lower EPS, although results still slightly beat expectations and guidance was reaffirmed.
Analyst sentiment is mixed but leaning cautious. Recent changes include Barclays raising its target to 27 with an Overweight rating, while Goldman Sachs cut its target to 17 and kept Neutral, and Citi downgraded Baxter to Sell with a target of 17. Overall, Wall Street pros see some valuation appeal and a modest beat/reaffirmed outlook on one side, but the more recent downgrades reflect concern about back-half weighting, margin pressure, and leadership/CFO uncertainty. Net view: pros are split, but the bearish calls have become more influential recently.
